Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Cencora, Inc.

Revenue

Revenue %Chg

Revenue Common Size

Cost of Goods Sold

Cost of Goods Sold %Chg

Cost of Goods Sold Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Distribution, Selling, and Administrative

Distribution, Selling, and Administrative %Chg

Distribution, Selling, and Administrative Common Size

Depreciation

Depreciation %Chg

Depreciation Common Size

Amortization

Amortization %Chg

Amortization Common Size

Warrants

Warrants %Chg

Warrants Common Size

Employee Severance, Litigation, and Other

Employee Severance, Litigation, and Other %Chg

Employee Severance, Litigation, and Other Common Size

Pension Settlement

Pension Settlement %Chg

Pension Settlement Common Size

Impairment of PharMEDium Assets

Impairment of PharMEDium Assets %Chg

Impairment of PharMEDium Assets Common Size

Litigation and Opioid-Related Expenses, Net

Litigation and Opioid-Related Expenses, Net %Chg

Litigation and Opioid-Related Expenses, Net Common Size

Acquisition, Integration, and Restructuring Expenses

Acquisition, Integration, and Restructuring Expenses %Chg

Acquisition, Integration, and Restructuring Expenses Common Size

Acquisition-Related Deal and Integration Expenses

Acquisition-Related Deal and Integration Expenses %Chg

Acquisition-Related Deal and Integration Expenses Common Size

Restructuring and Other Expenses

Restructuring and Other Expenses %Chg

Restructuring and Other Expenses Common Size

Goodwill Impairment

Goodwill Impairment %Chg

Goodwill Impairment Common Size

Impairment of Assets

Impairment of Assets %Chg

Impairment of Assets Common Size

Operating Income

Operating Income %Chg

Operating Income Common Size

Loss on Consolidation of Equity Investments

Loss on Consolidation of Equity Investments %Chg

Loss on Consolidation of Equity Investments Common Size

Other Loss, Net

Other Loss, Net %Chg

Other Loss, Net Common Size

Impairment Charge on Equity Investment

Impairment Charge on Equity Investment %Chg

Impairment Charge on Equity Investment Common Size

Interest Expense, Net

Interest Expense, Net %Chg

Interest Expense, Net Common Size

Loss on Early Retirement of Debt

Loss on Early Retirement of Debt %Chg

Loss on Early Retirement of Debt Common Size

Income Before Income Taxes

Income Before Income Taxes %Chg

Income Before Income Taxes Common Size

Income Tax Expense

Income Tax Expense %Chg

Income Tax Expense Common Size

Net Income

Net Income %Chg

Net Income Common Size

Net Loss Attributable to Noncontrolling Interests

Net Loss Attributable to Noncontrolling Interests %Chg

Net Loss Attributable to Noncontrolling Interests Common Size

Net Income Attributable to Cencora, Inc.

Net Income Attributable to Cencora, Inc. %Chg

Net Income Attributable to Cencora, Inc. Common Size

Basic

Basic %Chg

Basic Common Size

Diluted

Diluted %Chg

Diluted Common Size

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Depreciation & Amortization Expenses

Depreciation & Amortization Expenses %Chg

Depreciation & Amortization Expenses Common Size

Other Operating Expenses

Other Operating Expenses %Chg

Other Operating Expenses Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Interest Expense

Interest Expense %Chg

Interest Expense Common Size

Non-Operating Income

Non-Operating Income %Chg

Non-Operating Income Common Size

Total Non-Operating Income

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Total Revenues	321,332.8	316,654.4	310,232.2	303,192.8	293,958.6	283,830.8
Total Revenues %Chg	9.3%	11.6%	12.2%	11.6%	12.1%	11.6%
Revenue
Cost of Sales	309,854.3	305,637	299,711.2	293,193.6	284,048.6	274,159.8
Cost of Goods Sold
Gross Profit	11,478.5	11,017.4	10,521	9,999.3	9,910	9,671.1
Gross Profit
Gross Profit Margin	3.6%	3.5%	3.4%	3.3%	3.4%	3.4%
Selling, General & Administrative Expenses	6,493.8	6,235.3	5,945.6	5,734.4	5,661.1	5,564.6
Distribution, Selling, and Administrative
Depreciation & Amortization Expenses	1,051.1	1,069.3	1,087.9	1,099.9	1,092	1,091.2
Depreciation
Amortization
Other Operating Expenses	1,305	558	527.9	688.4	981.7	489.8
Warrants
Employee Severance, Litigation, and Other
Pension Settlement
Impairment of PharMEDium Assets
Litigation and Opioid-Related Expenses, Net
Acquisition, Integration, and Restructuring Expenses
Acquisition-Related Deal and Integration Expenses
Restructuring and Other Expenses
Goodwill Impairment
Impairment of Assets
Operating Profit	2,628.6	2,736.7	2,541.6	2,058.6	2,175.2	2,525.6
Operating Income
Operating Margin	0.8%	0.9%	0.8%	0.7%	0.7%	0.9%
Interest Expense	-291.5	-234.7	-184.2	-144.4	-157	-197
Interest Expense, Net
Non-Operating Income	78.7	-68.5	54.7	73.2	14.3	3.4
Loss on Consolidation of Equity Investments
Other Loss, Net
Impairment Charge on Equity Investment
Loss on Early Retirement of Debt
Total Non-Operating Income	-212.8	-303.2	-129.5	-71.1	-142.7	-193.6
Income Before Provision for Income Taxes	2,258.3	2,570.6	2,302.6	1,841	2,004	2,325.2
Income Before Income Taxes
Provision for Income Taxes	690.5	662.2	596.4	431	484.7	464.4
Income Tax Expense
Consolidated Net Income	1,567.8	1,908.4	1,706.2	1,410	1,519.3	1,860.8
Net Income Attributable to Minority Interests and Other	-13.6	-11.1	-12.9	-13.8	-10.2	-4.5
Net Loss Attributable to Noncontrolling Interests
Net Income Attributable to Common Shareholders	1,567.8	1,908.4	1,706.2	1,410	1,519.3	1,860.8
Net Income
Basic EPS	8	9.8	8.7	7.1	7.6	9.3
Diluted EPS	8	9.7	8.6	7	7.5	9.7
Basic Weighted Average Shares Outstanding	0.2	194.4	195.5	196.9	0.2	199.6
Total Shares Outstanding	193.9	193.9	193.8	193.8	194.9	197
Diluted Weighted Average Shares Outstanding	0.2	195.9	197.1	198.6	0.2	201.3
EBITDA	3,697	3,820.9	3,647.6	3,180.5	3,294.1	3,648.3
Effective Tax Rate	30.6%	25.8%	25.9%	23.4%	24.2%	20%